Add to ORKGThe evidence base relating to the use of everolimus in heart transplantation has expanded considerably in recent years, providing clinically relevant information regarding its use in clinical practice. Unless there are special considerations to take into
As the risk of graft loss due to acute rejection has declined, the goal of post-transplant managemen...
In a randomized, open-label trial, everolimus was compared to cyclosporine in 115 de novo heart tran...
Immunosuppression after liver transplantation (LT) is presently based on use of calcineurin inhibito...
The evidence base relating to the use of everolimus in heart transplantation has expanded considerab...
The evidence base relating to the use of everolimus in heart transplantation has expanded considerab...
Copyright © 2013 Stephan W. Hirt et al.This is an open access article distributed under theCreative ...
The efficacy of everolimus with reduced cyclosporine in de novo heart transplant patients has been d...
Since its introduction as an immunosuppressant in the late 1990s, sirolimus (SRL) has been used to p...
Safety of Early Everolimus in De Novo Heart Transplant Recipients: Interim Analysis of the Randomize...
OBJECTIVES: We examined the experiences of heart transplant recipients receiving everolimus as maint...
Everolimus is licensed for the prevention of acute rejection in heart or kidney transplant recipient...
In a randomized, open-label trial, everolimus was compared to cyclosporine in 115 de novo heart tran...
The role of everolimus in cardiac transplantation is being increasingly recognized.Multiple studies ...
Abstract: BACKGROUND: Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may s...
EARLY VERSUS DELAYED EVEROLIMUS INTRODUCTION IN HEART TRANSPLANTATION: ANALYSIS OF SAFETY ON THE FIR...
As the risk of graft loss due to acute rejection has declined, the goal of post-transplant managemen...
In a randomized, open-label trial, everolimus was compared to cyclosporine in 115 de novo heart tran...
Immunosuppression after liver transplantation (LT) is presently based on use of calcineurin inhibito...
The evidence base relating to the use of everolimus in heart transplantation has expanded considerab...
The evidence base relating to the use of everolimus in heart transplantation has expanded considerab...
Copyright © 2013 Stephan W. Hirt et al.This is an open access article distributed under theCreative ...
The efficacy of everolimus with reduced cyclosporine in de novo heart transplant patients has been d...
Since its introduction as an immunosuppressant in the late 1990s, sirolimus (SRL) has been used to p...
Safety of Early Everolimus in De Novo Heart Transplant Recipients: Interim Analysis of the Randomize...
OBJECTIVES: We examined the experiences of heart transplant recipients receiving everolimus as maint...
Everolimus is licensed for the prevention of acute rejection in heart or kidney transplant recipient...
In a randomized, open-label trial, everolimus was compared to cyclosporine in 115 de novo heart tran...
The role of everolimus in cardiac transplantation is being increasingly recognized.Multiple studies ...
Abstract: BACKGROUND: Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may s...
EARLY VERSUS DELAYED EVEROLIMUS INTRODUCTION IN HEART TRANSPLANTATION: ANALYSIS OF SAFETY ON THE FIR...
As the risk of graft loss due to acute rejection has declined, the goal of post-transplant managemen...
In a randomized, open-label trial, everolimus was compared to cyclosporine in 115 de novo heart tran...
Immunosuppression after liver transplantation (LT) is presently based on use of calcineurin inhibito...